FIELD: biotechnology.
SUBSTANCE: group of inventions relates to gene therapy. What is presented is a method for increasing the efficacy of the AAV-based gene therapy in a subject having anti-AAV neutralizing antibodies. Nipokalimab, an AAV vector containing a therapeutic heterologous polynucleotide, and IdeS or a modified variant thereof specified in any of SEQ ID NOs: 3–18, 23 or 48 are administered to the subject. There are also presented kits containing said nipokalimab, the AAV vector and IdeS or a modified version thereof.
EFFECT: inventions enable to reduce levels of neutralizing antibodies to the lowest titre levels in patients with high titres of NAb and provide effective AAV transduction for improving AAV-based gene therapy.
79 cl, 14 dwg, 9 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF Fc-REGION WITH ALTERED BINDING TO NEONATAL Fc-RECEPTOR (FcRn) FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2830231C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
| CARRIER CONTAINING A DRUG INTO A CELL FOR FORMING AN IMMUNE COMPLEX | 2012 |
|
RU2739792C1 |
| ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING TO A VARIETY OF ANTIGEN MOLECULES | 2018 |
|
RU2757786C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2017 |
|
RU2827545C2 |
